These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6299968)

  • 1. Ceftazidime, ceftizoxime, cefotaxime and HR 221 in experimental chronic Escherichia coli pyelonephritis in rats.
    Marre R; Herhahn D; Schulz E; Freiesleben H; Sack K
    Infection; 1983; 11 Suppl 1():S54-6. PubMed ID: 6299968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals.
    Klesel N; Limbert M; Schrinner E; Seeger K; Seibert G; Winkler I
    Infection; 1984; 12(4):286-92. PubMed ID: 6092278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].
    Tietgen K; Schulz E; Boness J; Marre R
    Immun Infekt; 1986 Jul; 14(4):152-5. PubMed ID: 2943665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic response of cephalosporin-treated E. coli pyelonephritis of the rat, in relation to variations of the infection model.
    Schulz E; Marre R; Herhahn D; Sack K
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):531-7. PubMed ID: 3901618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the effectiveness of cefazedone in experimental E. coli pyelonephritis.
    Sack K; Marre R; Freiesleben H; Henkel W
    Arzneimittelforschung; 1979; 29(2a):414-6. PubMed ID: 385009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftizoxime therapy of infections in hospitalized patients and comparison with cefamandole for urinary tract infections.
    Cohen E; Mogabgab WJ
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():253-60. PubMed ID: 6296017
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic properties of the newer cephalosporins. A valid basis for drug selection?
    Noble JT; Barza M
    Drugs; 1985 Sep; 30(3):175-81. PubMed ID: 3899596
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.
    Arai S; Hayashi S
    Infection; 1990; 18(3):186-90. PubMed ID: 2194972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.
    Bakker-Woudenberg IA; van den Berg JC; Michel MF
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1042-50. PubMed ID: 6297384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftizoxime and ceftazidime.
    Lancet; 1984 Feb; 1(8371):260. PubMed ID: 6143000
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of experimental ascending Escherichia coli pyelonephritis with ceftriaxone alone and in combination with gentamicin.
    Glauser MP; Bonard
    Chemotherapy; 1982; 28(5):410-6. PubMed ID: 6291870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime.
    Norrby SR
    Am J Med; 1985 Aug; 79(2A):56-61. PubMed ID: 3895919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.
    Neu HC
    Annu Rev Pharmacol Toxicol; 1982; 22():599-642. PubMed ID: 6282190
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
    J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of cefpirome, a new cephalosporin, on various models of infections in mice and rats.
    Arai S; Kobayashi S; Hayashi S
    Jpn J Antibiot; 1990 Jan; 43(1):1-8. PubMed ID: 2190011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiologic basis for the use of third-generation cephalosporins.
    Neu HC
    Am J Med; 1990 Apr; 88(4A):3S-11S. PubMed ID: 2183607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Third generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) in the prevention and treatment of experimental plague in albino mice].
    Ryzhko IV; Tsuraeva RI; Pasiukov VV; Samokhodkina ED; Shcherbaniuk AI
    Antibiot Khimioter; 1996 May; 41(5):35-8. PubMed ID: 9054316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cephalosporins in the treatment of meningitis.
    Neu HC
    Drugs; 1987; 34 Suppl 2():135-53. PubMed ID: 3319497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.